Receptor Partners

MycroDose Therapeutics is a U.S.-based pharmaceutical company focused on developing advanced drug delivery systems that utilize psychedelic compounds for the treatment of mental health disorders and cognitive degenerative diseases. The company is actively working on two of its four core technologies, which include a psilocybin transdermal delivery system and a ketamine oral mucosa delivery system. By leveraging these innovative approaches, MycroDose Therapeutics aims to enhance the efficacy and accessibility of treatments for patients dealing with these challenging conditions.

Mindstate Design Labs is a clinical-stage biotechnology company focused on developing innovative psychedelic-inspired therapeutics aimed at addressing intractable mental health conditions. By mapping the biological underpinnings of various psychedelic experiences, the company designs psychoactive effects intended for use in medically supervised environments. Their platform leverages a combination of natural history and computational methods to predict the acute effects of serotonergic agonists in humans. This allows healthcare institutions to effectively alter states of consciousness, facilitating the treatment of mental health disorders at their root.

Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases through the use of psychedelic compounds. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic derivative of psilocybin aimed at treating frontotemporal dementia. Psilera’s approach involves repurposing psychoactive natural products as foundational elements for next-generation therapies that enhance mental health. By prioritizing scientific excellence, Psilera seeks to transform the lives of individuals affected by cognitive, mood, and substance use disorders, marking a significant advancement in the field of mindful medicine.